Last reviewed · How we verify
NCT05938972: NASUMAB
Real Life Study of Biologicals in Patients With Severe CRSwNP
trial testing Mepolizumab in Chronic Rhinosinusitis With Nasal Polyps in 180 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 1 March 2022 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Mepolizumab (MEPOLIZUMAB) — full drug profile →
Conditions studied
- Chronic Rhinosinusitis With Nasal Polyps — all drugs for Chronic Rhinosinusitis With Nasal Polyps →
Sponsor
University Hospital, Ghent
Who can join
Adults 18 to 80, any sex, with Chronic Rhinosinusitis With Nasal Polyps. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. The aim of this study is to observe the long-term outcomes of biologicals in CRSwNP patients with or without comorbid asthma in 'real life'. Moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05938972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mepolizumab
Trials testing the same drug.
- NCT07200336 — Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP · Phase 4 · not yet recruiting
- NCT06107101 — th2 Modulation CRSwNP · Phase 4 · not yet recruiting
- NCT06041386 — REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEcti · Phase 4 · active not recruiting
- NCT05923047 — Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study. · Phase 4 · unknown
- NCT05642806 — Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment · Phase 4 · recruiting
Other recruiting trials for Chronic Rhinosinusitis With Nasal Polyps
Currently open trials in the same condition.
- NCT07187583 — Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps · Phase 4 · recruiting
- NCT06914908 — Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Poly · Phase 2 · recruiting
- NCT06834347 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Ina · Phase 3 · recruiting
- NCT06834360 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Ina · Phase 3 · recruiting
- NCT06706817 — A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initia · Phase 3 · recruiting
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05938972 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05938972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing